Bimatoprost — Active Pharmaceutical Ingredient

Bimatoprost is an active pharmaceutical ingredient found in 5 FDA-approved drug products. Forms: SOLUTION/DROPS, SOLUTION, IMPLANT, GEL. Routes: OPHTHALMIC, TOPICAL.

This content is for informational purposes only. Always consult a healthcare professional.

Bimatoprost (5 brand names, 4 dosage forms, 2 routes)

Available dosage forms: SOLUTION/DROPS, SOLUTION, IMPLANT, GEL.

Routes of administration: OPHTHALMIC, TOPICAL.

Brand Names

  • BIMATOPROST
  • DURYSTA
  • LATISSE
  • LUMIGAN
  • ZOLYMBUS

Indications and Usage

Bimatoprost ophthalmic solution 0.01% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

Dosage and Administration

The recommended dosage is one drop in the affected eye(s) once daily in the evening. Bimatoprost ophthalmic solution 0.01% should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the intraocular pressure lowering effect. Reduction of the intraocular pressure starts approximately 4 hours after the first administration with maximum effect reached within approximately 8 to 12 hours. Bimatoprost ophthalmic solution 0.01% may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

Contraindications

Bimatoprost ophthalmic solution 0.01% is contraindicated in patients with hypersensitivity to bimatoprost or to any of the ingredients [see Adverse Reactions (6.2)].

Adverse Reactions

The following adverse reactions are described elsewhere in the labeling: Pigmentation including blepharal pigmentation and iris hyperpigmentation [see Warnings and Precautions (5.1)] Eyelash Changes [see Warnings and Precautions (5.2)] Intraocular Inflammation [see Warnings and Precautions (5.3)] Macular Edema [see Warnings and Precautions (5.4)] Hypersensitivity [see Contraindications (4)]

Overdosage

No information is available on overdosage in humans. If overdose with bimatoprost ophthalmic solution 0.01% occurs, treatment should be symptomatic. In oral (by gavage) mouse and rat studies, doses up to 100 mg/kg/day did not produce any toxicity. This dose expressed as mg/m2 is at least 210 times higher than the accidental dose of one bottle of bimatoprost ophthalmic solution 0.01% for a 10 kg child.

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.